Neurocrine Biosciences (NBIX) Stock Forecast & Price Target

Neurocrine Biosciences Inc. is projected to achieve a FY27 EPS of $11.49, reflecting an optimistic outlook driven by revenue diversification, particularly with the introduction of the therapy Vykat. The company is expected to see the benefits of its recent deal become accretive by FY26, with anticipated increases in revenue and non-GAAP EPS over time, despite adjustments in SG&A expenses. Furthermore, strong existing therapies like Ingrezza provide a robust floor for the stock value, with expectations of continued growth fueled by a solid commercial infrastructure and new product launches expanding its market presence.

Neurocrine Biosciences faces a challenging outlook primarily due to the underperformance of Crenessity, which failed to sustain sales momentum and did not achieve projected sales of approximately $1 billion, attributed to market competition and patient compliance issues. Additionally, the company has raised its operational expenditure guidance significantly, particularly in research and development, indicating that these elevated costs will persist through 2028. The potential for regulatory setbacks and shrinking commercial opportunities due to competitive pressures and pricing constraints further compound the investment risks associated with Neurocrine Biosciences' prospects.